This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (67)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Ophthalmology  • Choroidal Neovascularization  • Diabetic Retinopathy  • Macular Degeneration  • Retinal/ Chorioretinal Disorders  • Alert me on articles by topic

Promises and Potential Problems

Peter van Wijngaarden, MBBS; Douglas J. Coster, MBBS, FRCS, FRANZCO; Keryn A. Williams, PhD

JAMA. 2005;293:1509-1513.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Molecular medicine offers promise for the prevention of vision loss caused by ocular neovascularization in diabetic retinopathy and exudative age-related macular degeneration (ARMD). During the past decade, significant advances have been made in angiogenesis research, such that the understanding about new vessel formation in disease has increased considerably. This knowledge has led to the development of numerous inhibitors of angiogenesis. Among a host of novel therapeutics for ocular neovascularization, 2 inhibitors of the angiogenic agent vascular endothelial growth factor (VEGF)—pegaptanib sodium and ranibizumab—are poised for imminent clinical application. However, the need for repeated intraocular injection of these agents and the potential for local and systemic adverse effects may pose hurdles for these emerging therapies.

Conventional Treatments Have Limitations

The proliferative retinopathies, principally diabetic retinopathy and exudative ARMD, are leading causes of vision loss worldwide, and their prevalence is projected to . . . [Full Text of this Article]

Author Affiliations: Department of Ophthalmology, Flinders University of South Australia, Adelaide, Australia.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Age-Related Macular Degeneration
Jager et al.
NEJM 2008;358:2606-2617.
FULL TEXT  

Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin
Izumi-Nagai et al.
IOVS 2008;49:1679-1685.
ABSTRACT | FULL TEXT  

Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas
Zhang et al.
Diabetes 2008;57:1026-1033.
ABSTRACT | FULL TEXT  

Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise
Ji et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H3740-H3749.
ABSTRACT | FULL TEXT  

Duplicate VegfA genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish
Bahary et al.
Blood 2007;110:3627-3636.
ABSTRACT | FULL TEXT  

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Bashshur et al.
Arch Ophthalmol 2007;125:1357-1361.
ABSTRACT | FULL TEXT  

The Role of VEGF and VEGFR2/Flk1 in Proliferation of Retinal Progenitor Cells in Murine Retinal Degeneration
Nishiguchi et al.
IOVS 2007;48:4315-4320.
ABSTRACT | FULL TEXT  

Interleukin-6 Receptor-Mediated Activation of Signal Transducer and Activator of Transcription-3 (STAT3) Promotes Choroidal Neovascularization
Izumi-Nagai et al.
Am. J. Pathol. 2007;170:2149-2158.
ABSTRACT | FULL TEXT  

VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle
Mac Gabhann et al.
J. Appl. Physiol. 2007;102:722-734.
ABSTRACT | FULL TEXT  

Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis
Dorrell et al.
Proc. Natl. Acad. Sci. USA 2007;104:967-972.
ABSTRACT | FULL TEXT  

A Prospective Study of 2 Major Age-Related Macular Degeneration Susceptibility Alleles and Interactions With Modifiable Risk Factors
Schaumberg et al.
Arch Ophthalmol 2007;125:55-62.
ABSTRACT | FULL TEXT  

What We Don't Know About Avastin Might Hurt Us
Gillies
Arch Ophthalmol 2006;124:1478-1479.
FULL TEXT  

Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization.
Bargagna-Mohan et al.
IOVS 2006;47:4138-4145.
ABSTRACT | FULL TEXT  

Pegaptanib: A Novel Approach to Ocular Neovascularization
Chapman and Beckey
The Annals of Pharmacotherapy 2006;40:1322-1326.
ABSTRACT | FULL TEXT  

A 76-year-old man with macular degeneration.
Arroyo
JAMA 2006;295:2394-2406.
FULL TEXT  

Expression of Protein Kinase CK2 in Astroglial Cells of Normal and Neovascularized Retina
Kramerov et al.
Am. J. Pathol. 2006;168:1722-1736.
ABSTRACT | FULL TEXT  

Pegaptanib Sodium (Macugen) for Macular Degeneration
Obstet Gynecol 2005;106:1100-1101.
FULL TEXT